Targeting CD44 augments the efficacy of Tregs in autoimmune diabetes

Immunology Letters

Volumn 163, Issue 2, 2015, Pages 199-205

  Li, Cheng Rui ^a   Mueller, Erin E ^a   Bradley, Linda M ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

CD44; Tregs; Type I diabetes

Indexed keywords

GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD44; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; BLOCKING ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES CONTROL; DRUG EFFICACY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; REGULATORY T LYMPHOCYTE; SHORT COURSE THERAPY; ANIMAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; NONOBESE DIABETIC MOUSE; PANCREAS; SCID MOUSE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD44; CD4-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MICE, INBRED NOD; MICE, SCID; PANCREAS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84921032218     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.10.002     Document Type: Article

References (28)

1. Herold K.C., Vignali D.A., Cooke A., Bluestone J.A. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013, 13:243-256.
2. Baaten B.J., Li C.R., Deiro M.F., Lin M.M., Linton P.J., Bradley L.M. CD44 regulates survival and memory development in Th1 cells. Immunity 2010, 32:104-115.
3. Weiss L., Slavin S., Reich S., Cohen P., Shuster S., Stern R., et al. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc Natl Acad Sci U S A 2000, 97:285-290.
4. Mrass P., Kinjyo I., Ng L.G., Reiner S.L., Pure E., Weninger W. CD44 mediates successful interstitial navigation by killer T cells and enables efficient antitumor immunity. Immunity 2008, 29:971-985.
5. Firan M., Dhillon S., Estess P., Siegelman M.H. Suppressor activity and potency among regulatory T cells is discriminated by functionally active CD44. Blood 2006, 107:619-627.
6. Liu T., Soong L., Liu G., Konig R., Chopra A.K. CD44 expression positively correlates with Foxp3 expression and suppressive function of CD4+ Treg cells. Biol Direct 2009, 4:40.
7. Bollyky P.L., Falk B.A., Long S.A., Preisinger A., Braun K.R., Wu R.P., et al. CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. J Immunol 2009, 183:2232-2241.
8. Godebu E., Summers-Torres D., Lin M.M., Baaten B.J., Bradley L.M. Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J Immunol 2008, 181:1798-1805.
9. Weber S.E., Harbertson J., Godebu E., Mros G.A., Padrick R.C., Carson B.D., et al. Adaptive islet-specific regulatory CD4T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J Immunol 2006, 176:4730-4739.
10. Li C.R., Deiro M.F., Godebu E., Bradley L.M. IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-beta7-dependent localization. J Autoimmun 2011, 37:217-227.
11. Wu C., Thalhamer T., Franca R.F., Xiao S., Wang C., Hotta C., et al. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 2014, 41:270-282.
12. Zhou X., Bailey-Bucktrout S., Jeker L.T., Bluestone J.A. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009, 21:281-285.
13. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009, 10:1000-1007.
14. McClymont S.A., Putnam A.L., Lee M.R., Esensten J.H., Liu W., Hulme M.A., et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011, 186:3918-3926.
15. Bailey-Bucktrout S.L., Martinez-Llordella M., Zhou X., Anthony B., Rosenthal W., Luche H., et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013, 39:949-962.
16. Grinberg-Bleyer Y., Baeyens A., You S., Elhage R., Fourcade G., Gregoire S., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010, 207:1871-1878.
17. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
18. Long S.A., Buckner J.H., Greenbaum C.J. IL-2 therapy in type 1 diabetes: trials and tribulations. Clin Immunol 2013, 149:324-331.
19. Li M.O., Flavell R.A. TGF-beta: a master of all T cell trades. Cell 2008, 134:392-404.
20. Lefebvre D.C., Lai J.C., Maeshima N., Ford J.L., Wong A.S., Cross J.L., et al. CD44 interacts directly with Lck in a zinc-dependent manner. Mol Immunol 2010, 47:1882-1889.
21. Foger N., Marhaba R., Zoller M. CD44 supports T cell proliferation and apoptosis by apposition of protein kinases. Eur J Immunol 2000, 30:2888-2899.
22. Mummert M.E., Mummert D., Edelbaum D., Hui F., Matsue H., Takashima A. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J Immunol 2002, 169:4322-4331.
23. Sakaguchi S., Yamaguchi T., Nomura T., Ono M., Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
24. McGregor C.M., Schoenberger S.P., Green E.A. CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes. Proc Natl Acad Sci U S A 2004, 101:9345-9350.
25. Rigby M.R., Trexler A.M., Pearson T.C., Larsen C.P. CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector T-cell inhibition and regulatory T-cell expansion. Diabetes 2008, 57:2672-2683.
26. Long S.A., Walker M.R., Rieck M., James E., Kwok W.W., Sanda S., et al. Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects. Eur J Immunol 2009, 39:612-620.
27. Weigand S., Herting F., Maisel D., Nopora A., Voss E., Schaab C., et al. Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist. Cancer Res 2012, 72:4329-4339.
28. Zhang S., Wu C.C., Fecteau J.F., Cui B., Chen L., Zhang L., et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A 2013, 110:6127-6132.